Nanobiotix SA
NBTX19.870USD
+0.200+1.02%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
958.02MCap. mercado
--P/E TTM
Más Datos de Nanobiotix SA Compañía
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Información de Nanobiotix SA
Símbolo de cotizaciónNBTX
Nombre de la empresaNanobiotix SA
Fecha de salida a bolsaOct 29, 2012
Director ejecutivoDr. Laurent Levy, Ph.D.
Número de empleados108
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 29
Dirección60 rue de Wattignies
CiudadPARIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísFrance
Código postal75012
Teléfono33140260470
Sitio Webhttps://www.nanobiotix.com
Símbolo de cotizaciónNBTX
Fecha de salida a bolsaOct 29, 2012
Director ejecutivoDr. Laurent Levy, Ph.D.
Ejecutivos de Nanobiotix SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Director
Independent Director
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Director
Independent Director
--
--
Dr. Louis Kayitalire, M.D.
Dr. Louis Kayitalire, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Brandon Owens
Mr. Brandon Owens
Vice President - Strategic Marketing and Corporate Communications
Vice President - Strategic Marketing and Corporate Communications
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Otro
88.30%
Accionistas
Accionistas
Proporción
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Otro
88.30%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
11.66%
Investment Advisor/Hedge Fund
0.02%
Research Firm
0.01%
Investment Advisor
0.01%
Otro
88.29%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
27
5.65M
11.71%
-4.13M
2025Q2
25
5.76M
12.15%
-4.19M
2025Q1
25
5.76M
12.15%
-4.19M
2024Q4
25
6.07M
12.79%
-4.24M
2024Q3
21
6.42M
13.54%
-3.89M
2024Q2
22
9.30M
19.73%
-1.04M
2024Q1
21
9.31M
19.76%
-988.94K
2023Q4
21
9.28M
19.68%
+1.01M
2023Q3
16
4.47M
12.36%
+481.67K
2023Q2
12
3.47M
9.94%
-1.27M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Johnson & Johnson Innovation-JJDC, Inc.
5.62M
11.66%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
10.18K
0.02%
--
--
Jun 30, 2025
Morgan Stanley & Co. International Plc
5.30K
0.01%
-800.00
-13.11%
Jun 30, 2025
UBS Financial Services, Inc.
4.42K
0.01%
+1.42K
+47.27%
Jun 30, 2025
BNP Paribas Securities Corp. North America
761.00
0%
+100.00
+15.13%
Jun 30, 2025
EverSource Wealth Advisors, LLC
517.00
0%
+517.00
--
Jun 30, 2025
RBC Capital Markets Wealth Management
125.00
0%
-11.00
-8.09%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
33.00
0%
--
--
Jun 30, 2025
Perceptive Advisors LLC
--
0%
-105.05K
-100.00%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares Biotechnology ETF
0%
iShares Biotechnology ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
